David Donabedian, PhDCEO, Co-Founder at Axial Biotherapeutics
David H. Donabedian, PhD, MBA, is co-founder and CEO of Boston-based Axial Biotherapeutics. Since Axial’s launch in November 2016, David has raised significant capital from top-tier VCs, assembled a renowned advisory and scientific board and established the company as a leader in the gut-brain-axis.
David was a strategy consultant at Accenture and applied his strong foundation in science and business at Surface Logix, where he headed the company’s business development efforts. His ability to develop successful business strategies and help launch innovative ideas led him to GlaxoSmithKline, where he took an active role in the ceedd leadership team. In 2012, he co-founded Alcyone Life Sciences, which is focused on the central nervous system disorders. In recognition of his skill in identifying future trends, he was recruited by AbbVie, where as VP, Head of Ventures & Early-Stage-Collaborations, he led a global team that managed a portfolio of biotech companies and successfully completed multiple transactions including M&A, licenses and option-deals. David is a Partner of Longwood Fund.
David holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina.